Persistent Pulmonary Hypertension of Newborn Clinical Trial
Official title:
Compare of Continued Nitro Oxide Inhalation and Nitro Oxide Inhalation Continued With Oral Sildenafil on Treatment of Neonatal Persistent Pulmonary Hypertension
Nitro Oxide (NO) inhalation was recognized as an effect treatment of Neonatal Persistent
Pulmonary Hypertension (PPHN), while the safety of NO long term application was under
investigation. Several research suggested too much NO2 was generated in the lung after long
term (> 72h) use of NO inhalation, which cause bad effects on PS production.
Sildenafil was proved to be effective to PPHN as NO. This medication has a similar clinical
effect but need monitoring of blood pressure. The possible hypotension effect restrict the
dosage of sildenafil, which limit the usage of sildenafil in severe PPHN. But we recommend
sildenafil to The purpose of the study was to establish if NO continued with sildenafil has
the same effect as single NO inhalation.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00981591 -
Inhaled Iloprost as an Adjunct to Inhaled Nitric Oxide in Pediatric Critical Care Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT01203423 -
Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study
|
||
| Withdrawn |
NCT01891500 -
Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure
|
Phase 4 | |
| Recruiting |
NCT04898114 -
Nebulized Magnesium Sulfate and Sildenafil for Persistent Pulmonary Hypertension of Newborn
|
Phase 1/Phase 2 | |
| Terminated |
NCT00443859 -
N-Terminal Pro-brain Natriuretic Peptide Hormone and Persistent Pulmonary Hypertension
|
N/A | |
| Completed |
NCT01757782 -
Oral Sildenafil in Persistent Pulmonary Hypertension Secondary to Meconium Aspiration Syndrome in Newborns
|
Phase 4 |